Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Pediatric Solid Tumors Clinical Trial

Official title:

Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01049841
• Other study ID #: 09-124
• Status: Completed
• Phase: Phase 1
• First received: January 14, 2010
• Last updated: March 9, 2017
• Start date: January 2010
• Est. completion date: March 2017

Study information

• Verified date: March 2017
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and effectiveness of 2 drugs, perifosine in combination with temsirolimus in children with solid tumors. Neither drug is currently part of the standard treatment of solid tumors in children. Both drugs have been tested alone to treat solid tumors in children with little success. There is now new insight that if given together, perifosine and temsirolimus may work together to stop the growth of solid tumors and may also make them shrink. The doctor wants to find out what effects; good and/or bad, perifosine in combination with temsirolimus has on the patient and the cancer. The doctors are testing four different dose schedules of perifosine with temsirolimus and the patient will be asked to partake in one of the dose schedules. The dose schedule will be lower for those enrolled early in the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• Any solid tumor that has failed standard therapy

• Patient must have evidence of tumor by CT, MRI, MIBG scan, serum markers, or tissue sampling.

• Age = 21 years (age = 35 years for biopsy proven medulloblastoma or neuroblastoma)

• Karnofsky/Lansky performance status = 50% (Karnofsky score for age> 16 years and Lansky score for age = 16 years)

• ANC= 1000 at least 24 hours off GCSF

• Platelets = 100K at least one week off platelet transfusions

• Hg= 8g/dL at least one week off PRBC transfusion

• AST = 2 x the upper limit of normal

• ALT = 2 x the upper limit of normal

• Total bilirubin = 2.0 mg/dl

• Patients must have cholesterol level < 350 mg/dl and triglycerides level < 400 mg/dl because temsirolimus can induce hyperlipidemia.

• Serum creatinine = 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear GFR = 70 ml/min/1.73 m2.

• = 3 weeks since last non-nitrosourea chemotherapy

• = 6 weeks since last nitrosoureas

• = 4 weeks since last RT

• Patients must agree to practice adequate contraception. Females of childbearing potential must have a negative serum B-HCG pregnancy test documented within 14 days prior to registration. Females must not be breast feeding.

• Patients must be able to swallow tablets whole

• Patients that participated in the phase I single agent perifosine study for recurrent pediatric solid tumors and did not experience a DLT are eligible to participate in this study and can start = 2 weeks since last dose of perifosine

• Patients that have been previously treated with an mTOR inhibitor can still enroll in this trial as long as they did not experience a DLT in the single agent mTOR inhibitor trial

Exclusion Criteria:

• Pregnancy

• Patients must not have an uncontrolled active infection.

• HIV-Positive patients receiving combination anti-retroviral therapy are excluded from the study due to possible retro-viral drug interactions. HIV testing not required.

• Patients must not be taking EIAEDs. If patients were previously on EIAEDs that have been discontinued, patients must have been off the agent for at least 2 weeks prior to registration.

• History of or known pulmonary hypertension or history of or known pneumonitis.

Related Conditions & MeSH terms

• Pediatric Solid Tumors

Intervention

Drug:
• perifosine + temsirolimus
The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (6)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	AEterna Zentaris, Duke University, NATL COMP CA NETWORK, Pfizer, University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) of perifosine + temsirolimus combination in children with cancer.		2 years
Secondary	To determine whether pharmacokinetic serum levels of both perifosine and temsirolimus correlate with toxicity.		2 years
Secondary	To record preliminary data on the efficacy of the perifosine + temsirolimus combination.		2 years
Secondary	If previously resected tissue is available, determine whether molecular features predict response including, Elevated PI3K/AKT/mTOR signaling, Elevated RAS/MAPK signaling, Cell cycle markers		2 years

External Links

•   Memorial Sloan-Kettering Cancer Center